Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

news: 2 news outlets
twitter: 11 tweeters

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 168 Dimensions

Readers on

mendeley: 150 Mendeley

Summary News Twitter Wikipedia Dimensions citations

So far, Dimensions has found 168 publications that cite this research output.

168

The most recent citing publications are shown below. View all 168 publications that cite this research output on Dimensions.

Hopf bifurcation without parameters in deterministic and stochastic modeling of cancer virotherapy, part I

Article in Journal of Mathematical Analysis and Applications (October 2022)

Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

Article in Acta Pharmacologica Sinica (August 2022)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

Article in BMC Cancer (August 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.